A Randomized, Crossover, Pharmacokinetic and Adhesion Performance Study of a Lidocaine Topical System 1.8% During Physical Activity and Heat Treatment in Healthy Subjects

This article was published in the following Dove Press journal: Journal of Pain Research

Jeffrey Fudin 1–4
Erica L Wegrzyn 1–3
Emileigh Greuber 5
Kip Vought 5
Kalpana Patel 5
Sri Nalamachu 6

1Samuel Stratton Department of Veterans Affairs Medical Center, Albany, NY, USA; 2Albany College of Pharmacy & Health Sciences, Albany, NY, USA; 3Western New England University College of Pharmacy, Springfield, MA, USA; 4Remitigate, LLC, Delmar, NY, USA; 5Scilex Pharmaceuticals Inc., Mountain View, CA, USA; 6Mid America Polyclinic, Overland Park, KS, USA

Purpose: This study compares the pharmacokinetic (PK) profile, adhesion, and safety of lidocaine topical system 1.8%, a novel lidocaine topical system approved to treat postherpetic neuralgia, under conditions of heat and exercise vs normal conditions.

Materials and Methods: This open-label, 3-period, 3-treatment crossover study randomized 12 healthy adults to receive three lidocaine topical systems 1.8% during each of three treatment periods, with 7-day washouts between treatments. The product was applied to the mid-lower back and was removed after 12 hours. During Treatment A, subjects exercised on a bicycle for 30 minutes at 0, 2.5, 5.5, and 8.5 hours. During Treatment B, heat (temperature set at 36.7–40.3°C) was applied at 0 and 8.5 hours. Treatment C was normal conditions. The PK profile of each subject under exercise and heat conditions was compared to normal conditions. Skin irritation, adhesion, and adverse events were assessed.

Results: Twelve subjects completed the study. Exposure to external heat resulted in increased peak plasma concentration of lidocaine with a mean Cmax of 160.3±100.1 ng/mL vs 97.6±36.9 ng/mL under normal conditions, with no effect on the extent of exposure (AUC). Concentrations returned to normal within 4 hours after the heat was removed. No clinically relevant differences in absorption were observed under exercise conditions with a mean Cmax of 90.5±25.4 ng/mL and no effect on the extent (AUC) of lidocaine exposure was observed relative to normal conditions. No systems detached during the study. Adverse events were mild, with none leading to discontinuation.

Conclusion: Transient heat exposure resulted in increased lidocaine plasma concentrations compared to normal conditions, whereas exercise had no effect. The effects of heat appear to be immediate, reversible, and below systemic therapeutic threshold in antiarrhythmic treatment (1000–1500 ng/mL), and well below the safe systemic threshold of 5000 ng/mL. Lidocaine topical system 1.8% remained adhered to the skin and was well tolerated under all conditions. ClinicalTrials.gov: NCT04150536.

Keywords: herpes zoster, shingles, neuropathic pain, dermal

Introduction
Postherpetic neuralgia (PHN) is a chronic neuropathic pain condition that is a common complication of herpes zoster virus infections (shingles), particularly in older patients. The pain may persist for several (>3) months after the rash has resolved and is described as burning, sharp, jabbing, deep, and aching; it may be associated with allodynia. Itching and numbness have also been reported. PHN
presents a significant individual and societal healthcare burden, but is often undiagnosed and poorly managed, with a 30% pain reduction considered clinically significant but a goal that is only met about 50% of the time.1

Before prescribing treatment for PHN, providers must consider several patient-specific factors, such as age, comorbidities, and any medications used for treating comorbidities, to avoid potentially additive side effects. As the incidence of PHN increases with age,2 it is also important to consider age-related physiologic changes and pharmacokinetic (PK) implications, including impaired hepatic and renal function, that can increase the risk of adverse events (AEs).3 This is important given the potential AE profiles of oral medications for PHN that may include serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, gabapentinoids, anticonvulsants, and opioids.4–6

Lidocaine is an amide local anesthetic agent that stabilizes neuronal membranes by inhibiting the ionic fluxes required for initiation and conduction of impulses. Application of topical lidocaine has been shown to be efficacious for the treatment of neuropathic pain, with a low risk of systemic effects.1,2 ZTlido® is a novel lidocaine topical system (Scilex Pharmaceuticals Inc., Mountain View, CA, USA) that was approved by the US FDA in 2018 for the relief of pain associated with PHN. Each topical system contains 36 mg of lidocaine in a thin, nonaqueous adhesive matrix (18 mg per gram adhesive: 1.8%).7 Lidocaine topical system 1.8% was developed to deliver a bioequivalent level of the drug as Lidoderm® (lidocaine patch 5%; Endo Pharmaceuticals, Malvern, PA, USA), a hydrogel patch containing 700 mg of lidocaine.8 Like Lidoderm, ZTlido was designed to deliver sufficient lidocaine to produce an analgesic effect, but less than that needed to produce a complete sensory block.7

Systemic lidocaine exposure from topically applied patches (now referred to as “topical systems” by FDA) is limited under normal wear conditions. For many drugs, however, delivery through the skin, and thus serum drug concentrations, can be affected by heat and exercise, which may alter circulation and blood flow, resulting in increased drug delivery and higher drug exposure.9,10 It is known that the absorption of local anesthetic agents, including lidocaine, from topical creams, can be increased if skin temperature is elevated by exercising, covering the skin, or using an external heat source.11 There have been reports of serious adverse events, including irregular heartbeat, seizures, difficulty breathing, and death after the improper use of local anesthetic numbing creams.1 The concentration of lidocaine required for systemic toxicity is ≥5000 ng/mL12 which is several-fold higher than the systemic exposure from prescription lidocaine patches and systems (~100 ng/mL) under normal use conditions.7,8 The effects of heat and exercise on drug delivery are dependent on many factors, including drug load, concentration, and the inactive ingredient composition, and should, therefore, be determined on a product-specific basis.

Adhesion under conditions of heat and exercise is also a potential concern, as drug delivery depends on product adherence to the skin throughout the administration period. Activities of daily living can impact the application of topical systems and ultimately decrease efficacy if dermal adhesion is poor.

Consistent with regulatory expectations and to appropriately characterize and label the product, this study was conducted to characterize the PK and adhesion of lidocaine topical system 1.8% under conditions of heat and exercise.

**Materials and Methods**

**Measures and Outcomes**

This open-label, randomized, 3-treatment, 3-sequence, 3-period crossover study was conducted at one clinical site (AXIS Clinicals, Dilworth, MN, USA) in accordance with ICH Guideline for Good Clinical Practice (GCP), approved by Salus Institutional Review Board (IRB), and conducted in accordance with the Declaration of Helsinki. The bioanalytical facility was blinded to the randomization code. This study was registered with ClinicalTrials.gov, NCT04150536.

**Study Objectives**

The primary objective of this study was to evaluate the PK characteristics and adhesion performance of lidocaine topical system 1.8% (administered as 3 topical systems) in fasting healthy human subjects during physical exercise, heat exposure, and normal conditions. The secondary objective was to conduct a formal irritation assessment at the end of each treatment period and to monitor AEs and safety concerns in healthy subjects with the use of the product.

**Subjects**

Eligible men and women were 18 years of age and older, with a body mass index (BMI) between 18.00 and 32.49 kg/m². Subjects were generally healthy, as documented by medical history, physical examination, and
vital signs assessments, with no evidence of underlying
disease during check-in and screening performed within
28 days of check-in. Female subjects were not pregnant
and used contraception during the study if they were of
child-bearing potential. All subjects provided written
informed consent and were able to comply with study
procedures.

Exclusion Criteria
Subjects were excluded if they had any major medical
illness 3 months prior or any significant history or ongoing
chronic medical illness affecting the major body systems,
including the skin; allergy or known hypersensitivity to
lidocaine, amide-type local anesthetics, or any component
of the product formulation. Subjects with conditions that
might affect the application of the product or its adhesive
properties (including psoriasis, eczema, atopic dermatitis,
damaged or irritated epidermal layer, and excessive hair or
oil on the skin) were excluded. History of addiction, abuse,
and misuse of any drug; use of any nicotine-containing
products within 30 days; or alcohol abuse within 12
months prior to product application were also reasons for
study exclusion.

Treatments
Per randomization schedule, all subjects received three
lidocaine topical systems 1.8%, each containing 36 mg
of lidocaine, during three separate treatment periods
(Period-I, Period-II, Period-III). Each period included
four subjects per treatment (Treatments A, B, C).
Subjects were randomized to three different treatment
sequences (ABC, BCA, and CAB). In each period, the
product was applied to clean, dry skin that was free of
lotion, soap, or oil in the mid-lower back after an over-
night fast (≥10 hours) in each of three randomly allocated
treatment plans, with a 7-day washout between treatments.
The three topical systems (total lidocaine dose of 108 mg)
were each worn for 12 hours. No overlays, adhesive tape,
or similar products were applied.

- Treatment A: 3 lidocaine topical systems 1.8% with
  physical exercise
- Treatment B: 3 lidocaine topical systems 1.8% with
  application of heat
- Treatment C: 3 lidocaine topical systems 1.8% under
  normal conditions

Physical Exercise
Subjects were instructed to perform an exercise regimen for
30 minutes on an exercise bicycle (Exerpeutic 1000-High
Capacity Magnetic Recumbent Exercise Bike, Exerpeutic,
China), achieving a heart rate of approximately 108 beats
per minute. Exercise was performed immediately after pro-
duct application and at 2.5, 5.5, and 8.5 hours after product
application, with a window of ±10 minutes. Heart rate was
continuously monitored during exercise.

Heat Application
Heat was applied using a standard 3-setting heating pad
(CVS XL 3 Setting Moist Dry Heating Pad and
Controller), with precautions followed for heat applica-
tion per manufacturer guidelines (ie, a blanket or towel
placed between the pad and the product to reduce risk of
skin burning). The temperature was set on “medium”
(36.7–40.3°C tested over 1 hour with Etekcity Lasergrip
774 Infrared Thermometer, Etekcity Corporation,
Anaheim, CA, USA), and the heating pad was applied
for 20 minutes immediately and at 8.5 hours after product
application.

Study Assessments
The PK of each treatment condition was evaluated by the
estimation of lidocaine concentrations in plasma, using
a validated liquid chromatography–tandem mass spectro-
metry (LC-MS/MS) method. The calibration range of the
procedure was 0.2000 ng/mL to 200.0 ng/mL, with a lower
limit of quantification of 0.2000 ng/mL. PK parameters
such as maximum plasma concentration (C_max), area under
the plasma concentration–time curve between times zero
and t (AUC_{0–t}), AUC between time zero and infinity
(AUC_{0–∞}), time to C_max (t_{max}), percentage extrapolation
(calculated as AUC_{%extrapolation}=[AUC_{0–∞}/AUC_{0–t}] ×100/AUC_{0–∞}), elimination rate constant (K_e), and elim-
ination half-life (t_{1/2}) were calculated following blood
collection by venipuncture pre-dose and at 2, 4, 6, 9, 10,
11, 12, 13, 14, 16, 18, 20, 22, 24, and 48 hours post-dose.

Skin irritation at the lidocaine topical system applica-
tion site was evaluated pre-application (0 hours), 30
minutes (with a window period of ±10 minutes) after
product removal and 2 hours after product removal
using the FDA-recommended 8-point scale of dermal
response (0=no evidence of irritation; 1=minimal
erythema, barely perceptible; 2=definite erythema;
3=erythema and papules/pustules; 4=definite edema;
5=erythema, edema, and papules; 6=vesicular eruption;
Product adhesion was assessed were lower during physical exercise (Treatment A) (Table 2).

Table 2

| Parameter        | N=12            |
|------------------|-----------------|
| Age, years, mean±SD (range) | 46.17±15.94 (19–62) |
| Sex, n, M/F      | 3/9             |
| Race, n, Black/White | 1/11           |
| BMI, kg/m² (mean±SD) | 27.81±2.91     |

### Adverse Events and Safety

AEs were recorded after spontaneous reporting by subject or physician observation within ±30 minutes of the scheduled time. Vital sign assessments (blood pressure, heart rate, respiratory rate and temperatures) were taken at pre-dose, 4, 10, and 24 hours post-dose. A 12-lead electrocardiogram was recorded at screening (all within normal limits).

### Results

#### Subject Disposition and Baseline Characteristics

A total of 12 subjects, aged between 19 and 62 years with BMI values between 21.95 and 30.91 kg/m² (Table 1), completed the study. Subjects were randomized to each of the three treatments according to the predetermined schedule; all subjects completed their assigned schedule without any discontinuations or withdrawals. Plasma concentrations of 12 subjects were included in PK and statistical analyses; all subjects were included in the adhesion analysis.

#### PK Assessments

##### Comparison of Physical Exercise and Normal Conditions

Mean values of the primary PK parameters $C_{\text{max}}$, $AUC_{0-\infty}$, and $AUC_{0-t}$ were lower during physical exercise (Treatment A) than during normal conditions (Treatment C) by 7%, 11%, and 10%, respectively.

The 90% confidence interval for physical exercise (Treatment A) vs normal conditions (Treatment C) ratios of Ln-transformed PK parameters fell within the range of 79.65 to 112.73, suggesting that the effects of physical exercise on the rate and extent of lidocaine absorption from the topical system were not significant (Figure 1, Tables 2 and 3).

The median plasma lidocaine $t_{\text{max}}$ was 9 hours for physical exercise (Treatment A) and 11.5 hours for normal conditions (Treatment C). The observed half-life was similar for Treatment A (5.602 hours) and Treatment C (5.230 hours) (Figure 1, Tables 2 and 3).

### Statistical Analysis

The randomization schedule was prepared using SAS® Release 9.4 (SAS Institute Inc., Cary, NC, USA). Data set preparation and analysis of the PK parameters were performed using a non-compartmental model with WinNonlin Professional Software version 5.01 (Pharsight Corporation, Sunnyvale, CA, USA).

Descriptive statistics were computed for all PK parameters for lidocaine topical system 1.8% (total lidocaine dose=108 mg) under each treatment condition (exercise, heat, and normal). Bioequivalence comparisons of PK parameters for the exercise and heat treatments vs normal conditions were performed using PROC GLM of SAS® Release 9.4. Analysis of variance (ANOVA) was calculated for untransformed and natural log-transformed $C_{\text{max}}$, $AUC_{0-\infty}$, and $AUC_{0-t}$ using the treatment received, the period at which it was given, the sequence of treatment, and the subject effect (nested within the sequence). Sequence effect was tested using the subject nested within sequence mean square from the ANOVA as the error term. ANOVA calculations included least square mean. The level of significance was set at $\alpha=0.05$, except for the significance of the sequence effect involved in the model (set at $\alpha=0.1$). 90% confidence intervals (CIs) for the ratio of the Treatments (A, B and C) products averages (geometric least-square means) were calculated by first calculating the 90% CI for the differences in the averages (least-square means) of the log-transformed data and then taking the antilogs of the obtained confidence limits. By convention, if the 90% CI of the ratio of geometric means was within 80% to 125%, then the treatments were considered bioequivalent.

Statistical Analysis

7=strong reaction spreading beyond the test site) and a scale of other effects (including glazed appearance, peeling and cracking, dried serous exudates covering at least part of the application site, and small petechial erosions and/or scabs). Product adhesion was assessed immediately after (0 hours) and at 0.5, 3, 6, 9, and 12 hours (before system removal) after application, with a degree of adhesion recorded using the FDA-recommended rating scale, where 0: ≥90% adhered (essentially no lift off the skin); 1: ≥75% to <90% adhered (some edges only lifting off the skin); 2: ≥50% to <75% adhered (less than half the system lifting off the skin); 3: <50% adhered but not detached (more than half the system lifting off the skin without falling off); and 4: 0% (complete detachment).

For personal use only.

---

Table 1

Demographics and Baseline Characteristics

| Characteristic          | N=12 |
|-------------------------|------|
| Age, years, mean±SD (range) | 46.17±15.94 (19–62) |
| Sex, n, M/F             | 3/9  |
| Race, n, Black/White    | 1/11 |
| BMI, kg/m² (mean±SD)    | 27.81±2.91 |
Comparison of Heating and Normal Conditions
The mean values of $C_{\text{max}}$, $AUC_{0-t}$, and $AUC_{0-\infty}$ were higher during heat application (Treatment B) than during normal conditions (Treatment C) by 64%, 16%, and 15%, respectively (Figure 1, Tables 2 and 3).

The 90% confidence interval for heat application (Treatment B) vs normal conditions (Treatment C) ratios of $C_{\text{max}}$ (123.71–173.66 ng/mL) fell outside the 80% to 125% limits that are standard for bioequivalence determination, suggesting that heat exposure caused a significant increase in lidocaine absorption, resulting in a higher $C_{\text{max}}$ than under normal conditions (Figure 1, Tables 2 and 3).

The corresponding ranges for $AUC_{0-t}$ (95.34–122.40 h·ng/mL) and $AUC_{0-\infty}$ (95.46–121.79 h·ng/mL) were within the 80% to 125% range, suggesting that the effects of heating on these parameters were not significant (Figure 1, Tables 2 and 3).

Table 2 Summary Statistics of Pharmacokinetic Parameters of Lidocaine Topical System 1.8% with Physical Exercise, Heating, and Normal Conditions

| Statistics | $C_{\text{max}}$ (ng/mL) | $AUC_{0-t}$ (h·ng/mL) | $AUC_{0-\infty}$ (h·ng/mL) | $AUC%$ Extrapolation | $t_{\text{max}}$* (h) | $K_{el}$ (h$^{-1}$) | $t_{1/2}$ (h) |
|------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Treatment A | N 12 | 90.48 | 1328.81 | 1344.08 | 12 | 90.0 | 12 | 12 |
| Mean       | 12 | 90.48 | 1328.81 | 1344.08 | 12 | 90.0 | 12 | 12 |
| SD         | 25.413 | 461.660 | 458.187 | 34.7 | 2.211 | 162.3 | 0.13 | 12 |
| CV (%)     | 28.1 | 9.00 | 49.0 | 0.13 | 5.60 | 12.9 | 1.13 | 19.9 |
| Treatment B | N 12 | 160.28 | 1718.71 | 1731.272 | 12 | 90.0 | 12 | 12 |
| Mean       | 12 | 160.28 | 1718.71 | 1731.272 | 12 | 90.0 | 12 | 12 |
| SD         | 100.061 | 1004.005 | 1005.036 | 58.4 | 1.112 | 124.0 | 0.14 | 5.39 |
| CV (%)     | 62.4 | 30.0 | 0.029 | 1.338 | 1.338 | 12.9 | 5.39 | 24.8 |
| Treatment C | N 12 | 97.59 | 1487.39 | 1501.10 | 12 | 90.0 | 12 | 12 |
| Mean       | 12 | 97.59 | 1487.39 | 1501.10 | 12 | 90.0 | 12 | 12 |
| SD         | 36.869 | 590.007 | 588.428 | 39.7 | 1.535 | 143.2 | 0.14 | 5.23 |
| CV (%)     | 37.8 | 39.2 | 18.9 | 1.203 | 1.203 | 21.5 | 23.0 |

Notes: *For $t_{\text{max}}$, median and range have been represented instead of mean and SD. Treatment A: with physical exercise; Treatment B: with heating; Treatment C: under normal conditions.

Abbreviations: SD, standard deviation; CV, coefficient of variation.
Figure 1 shows that the effects of heating were mainly evident at the 9-hour time point (immediately following 20 minutes of heating starting at 8.5 hours), with little difference observed among the three treatments at other time points at which lidocaine concentrations were measured (Figure 1, Tables 2 and 3).

Lidocaine concentrations at 9 hours were 171.8±96.3 ng/mL after heating compared with 88.5±25.4 ng/mL for Treatment A and 92.9±39.7 ng/mL for Treatment C (Figure 1, Tables 2 and 3).

Thus, the effects of heating on lidocaine absorption appeared to be immediate and reversible, with no suggestion of dose dumping or discontinuation of drug delivery. Given the timing of heat application used in this study, heating increased the Cmax via an immediate effect at the 9-hour time point, with the little overall effect on the AUC.

The median tmax was 9 hours for Treatment B and 11.5 hours for Treatment C. The observed half-life was similar for Treatment B (5.390 hours) and Treatment C (5.230 hours) (Figure 1, Tables 2 and 3).

The observed intrasubject coefficient of variation for Cmax was found to be 24.4%, indicating a higher variability in exposure during Treatment B (Figure 1, Tables 2 and 3).

**Adhesion and Irritation Analysis**

Adhesion analysis included all topical systems from 12 subjects; no systems detached during the study across all three treatment periods or were removed early for unacceptable irritation, and no subjects dropped out of the study before the end of the 12-hour application period (Table 4). The mean irritation scores for 12 subjects for all treatments were <1 (1=minimal erythema) after product removal.

Under normal conditions (Treatment C), all subjects had ≥90% adhesion throughout the administration period. Under heat conditions (Treatment B), a slight degree of lifting (score of 1, ≥75% to <90%) was observed for 2 subjects at 9 and 12 hours, respectively, and at 12 hours for a third subject. Product lifting was observed for 6 subjects (50%) under exercise conditions (Treatment A), with 2 subjects having a score of 2 (≥50% to <75% adhered) at some point during the 12-hour administration period. Three subjects observed to have lifting after exercise had improved adhesion at later time points within the 12-hour administration period. No subject was observed to have a score of ≥3 (>0% to <50% adhered) or complete detachment.

**Adverse Events and Safety**

A total of six AEs were spontaneously reported by four subjects during the study (Table 5); three events occurred in two subjects in Period-I. One of these subjects had a headache (twice), which was considered possibly related to the study drug and treatment (Treatment B; heat). The second subject reported lightheadedness secondary to exercise treatment (Treatment A), which was considered

**Table 3** Geometric Least Square Mean, Ratios, 90% Confidence Interval, ISCV and Power for Lidocaine Topical System 1.8% (in Transformed Data)

| Parameter | Geometric Mean | Intra-Subject CV (%) | (A/C) Ratio, % | 90% Confidence Intervals (A/C) | (B/C) Ratio, % | 90% Confidence Intervals (B/C) |
|-----------|----------------|----------------------|---------------|-----------------------------|---------------|-----------------------------|
| Cmax, ng/mL | Treatment A 87.27 134.44 91.72 24.4 95.14 80.30–112.73 | Treatment B 1264.16 1513.10 1400.70 17.9 90.25 79.65–102.26 | Treatment C 1281.92 1526.88 1416.04 17.4 90.53 80.15–102.25 | | | |
| AUCdm, h ng/mL | Treatment A 112.73 146.57 123.71–173.66 | Treatment B 122.40 108.02 95.34–122.40 | Treatment C 121.79 140.07 95.46–121.79 | | | |

**Notes:** Treatment A: with physical exercise; Treatment B: with heating; Treatment C: under normal conditions.

**Abbreviations:** ISCV, intrasubject coefficient of variation; CV, coefficient of variation.

**Table 4** Summary Statistics of Adhesion Performance Evaluation of Lidocaine Topical System 1.8% with Physical Exercise, Heating, and Normal Conditions

| Statistics | Treatment | N | Minimum | Maximum | Mean | SD | CV (%) |
|------------|-----------|---|---------|---------|------|----|-------|
| Adhesion Score | A 12 | 0 | 2 | 0.33 | 0.389 | 116.8 |
| | B 12 | 0 | 1 | 0.07 | 0.132 | 190.3 |
| | C 12 | 0 | 0 | 0.00 | 0.000 | 0 |

**Notes:** Treatment A: with physical exercise; Treatment B: with heating; Treatment C: under normal conditions.

**Abbreviations:** SD, standard deviation; CV, coefficient of variation.
unrelated to the study drug. Another AE (headache) was reported in a subject during Period-II (Treatment C), which was considered possibly related to the study drug.

AEs considered unrelated to the study drug were one subject with menstrual cramps during the Period-I washout. Another subject reported a head cold in Period-III that was also not considered related to the study drug.

The most common AE was headache, which occurred in three subjects. No deaths or serious AEs were reported during the study. Vital assessments conducted throughout all treatment periods were within normal limits for all subjects.

**Discussion**

The results of this study show that the effects of four 30-minute episodes of physical exercise on the rate and extent of lidocaine absorption from topical system 1.8% were not significant, thus, allowing for safe use of the product during moderate physical activity, as reflected in the product’s prescribing information.7

Localized heating of lidocaine topical system 1.8% for 20 minutes at two different time periods resulted in a significant increase in lidocaine absorption, reflected in a higher C\text{max} than that observed under normal conditions, but did not significantly impact the extent of drug delivery (AUC\text{0-4} or AUC\text{0-\infty}). The effects of heat on absorption appeared to be immediate and reversible, showing that the product does not undergo dose dumping or discontinuation of drug delivery. While heat exposure induces a significant increase in C\text{max}, the level observed (172 ng/mL) was well below the systemic safety threshold of 5000 ng/mL for the avoidance of related AEs and the IV levels used to treat cardiac arrhythmias (1000–1500 ng/mL).12 These changes appear generally consistent with data in the literature for other topical and transdermal products and are an expected thermodynamic outcome.10

Subjects were generally healthy, and vital signs were within normal ranges at rest, during heat exposure, and during physical activity. Overall, the application of lidocaine topical system 1.8% was well tolerated; six AEs reported by four subjects, with the most common AE being headache. Of the six reported AEs, only three were considered associated with the study drug, all of which were headache and observed in the same subject. No localized dermatologic AEs (i.e., irritation, itching, blisters) were reported by any subject.

Limitations of the present study include the small size of the study population (N=12), ECG monitoring at baseline only and the lack of a comparator. Comparative examinations of the effects of heat and exercise between lidocaine topical system 1.8% and lidocaine patch 5% would have been of interest and should be investigated further. However, the potential deleterious effects (e.g., complete or partial dose-dump of drug) of these conditions with lidocaine patch 5% cannot be reasonably hypothesized or safe-guarded relative to the high drug load within the product (700 mg). The extent and seriousness of heat exposure effects on in vivo drug absorption, pharmacodynamics, and possible adverse events of topical products are dependent on the physicochemical and pharmacological properties of the drug(s) and the drug delivery system formulation design and need to be evaluated on a case-by-case basis.15

**Conclusion**

The results of this study show that administration of three lidocaine topical systems 1.8%, each containing 36 mg of active compound produced sustained plasma lidocaine concentrations and was well tolerated in healthy subjects under normal conditions, with physical exercise, and with localized heating for 20 minutes with a heating pad. There was no significant effect observed on the PK profile under the exercise conditions. While heat exposure induces a significant increase in C\text{max}, the concentrations observed are well below (~30-fold) the systemic safety threshold for the avoidance of related AEs and 6- to 10-

Table 5 Summary of Adverse Events

| Subject Number | Period Number | Treatment Received | Adverse Event                          | Severity | Related to Drug |
|----------------|---------------|---------------------|---------------------------------------|----------|-----------------|
| S04            | III           | B                   | Head cold                             | Mild     | Not related     |
| S05            | I             | B                   | Headache                              | Moderate | Possibly related |
|                | II            | C                   | Headache                              | Mild     | Possibly related |
| S09            | I (Washout)   | A                   | Menstrual cramps                      | Mild     | Not related     |
| S12            | I             | A                   | Light headedness secondary to exercise | Mild     | Not related     |

Notes: Treatment A: with physical exercise; Treatment B: with heating; Treatment C: under normal conditions.
fold below the IV levels used to treat cardiac arrhythmias. Adequate adhesion of the system was maintained under both conditions, and the dermal irritation profile was benign.

Data Sharing Statement

The authors certify that this manuscript reports original clinical trial data. Individual participant data that underlie the results reported in this article after deidentification (text, tables, figures, and appendices) are available from Medical Affairs Department at Scilex Pharmaceuticals Inc. at Medical_Affairs@scilexpharma.com including the study protocol. Data requests should be submitted in the form of a research proposal for up to 36 months after the publication date.

Ethics Approval and Informed Consent

The sponsors and investigators state that they have obtained appropriate IRB approval from Salus Institutional Review Board in Austin, Texas or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

Acknowledgments

The authors would like to thank the investigators, their clinical staff, and the subjects who made this study possible. Nirzari Parikh, PhD, of Synergy Medical Education, provided medical writing support. This article is the sole work of the authors; stated opinions or assertions do not reflect the opinions of employers or employee affiliates listed. The article was not prepared as part of the authors’ duties as federal employees where applicable.

Funding

The project supported by Shandong Key Research and development Program (Grant No. 2018GSF118110).

Disclosure

Dr Jeffrey Fudin is a speaker for Abbott Laboratories, AstraZeneca, and Acutis Diagnostics, Inc; part of the advisory board, speakers bureau, and consulting for AcelRx Pharmaceuticals, BioDelivery Sciences International, GlaxoSmithKline (GSK), Salix Pharmaceuticals, and Daiichi-Sankyo Incorporated; received non-financial support by collaborating publications for Scilex Pharmaceuticals; consultant for Firstox; advisory board for Human Half-Cell, Inc and Quest Diagnostics, outside the submitted work. Drs. Greuber, Vought, and Patel are full-time employees of Scilex Pharmaceuticals Inc. Dr Vought has a patent 62/762,753 pertaining to Scilex Pharmaceuticals Inc and was responsible for the design and conduct of the study. Dr. Nalamachu has been a consultant/speaker and has received an honorarium from BDSI, DSI, Endo, Insys, Scilex Pharmaceuticals Inc., Purdue, Pfizer Inc., Eli Lilly and Company, Collegium Pharmaceutical, Perinnix Therapeutics, Daiichi-Sankyo, and AstraZeneca. Dr Erica Wegrzyn reports personal fees from Remitigate LLC and Tower Health Pain & Addiction Symposium; is an Associate Editor in Chief for Journal of Pain Research, outside the submitted work. The authors report no other conflicts of interest in this work.

References

1. Hadley GR, Gayle JA, Ripoll J, et al. Post-herpetic neuralgia: a review. Curr Pain Headache Rep. 2016;20(3):17.
2. Mallieck-Searle T, Snodgrass B, Brant JM. Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology. J Multidiscip Health. 2016;9:447–454. doi:10.2147/JMDH.S106340
3. Bettinger JJ, Wegrzyn EL, Fudin J. Pain management in the elderly: focus on safe prescribing. Pain Pract Manag. 2017;17(3).
4. Shrestha M, Chen A. Modalities in managing postherpetic neuralgia. Korean J Pain. 2018;31(4):235–243. doi:10.3344/kjp.2018.31.4.235
5. Fornasari D. Pharmacotherapy for neuropathic pain: a review. Pain Ther. 2017;6(Suppl 1):25–33. doi:10.1007/s40122-017-0091-4
6. Massengill JS, Kittredge JL. Practical considerations in the pharmacological treatment of postherpetic neuralgia for the primary care provider. J Pain Res. 2014;7:125–132. doi:10.2147/JPR.S57242
7. ZTLIDO® (Lidocaine Topical System): Prescribing Information. San Diego, California, USA: Scilex Pharmaceuticals; 2018.
8. LIDOEM® (Lidocaine Patch 5%): Prescribing Information. Malvern, Pennsylvania, USA: Endo Pharmaceuticals; 2018.
9. Lenz TL. The effects of high physical activity on pharmacokinetic drug interactions. Expert Opin Drug Metab Toxicol. 2011;7(3):257–266. doi:10.1517/17425255.2011.533190
10. Vanakoski J, Seppala T. Heat exposure and drugs: a review of the effects of hyperthermia on pharmacokinetics. Clin Pharmacokinet. 1998;34(4):311–322. doi:10.2165/00003088-199834040-00004
11. US Food and Drug Administration. Public health advisory: life-threatening side effects with the use of skin products containing numbing ingredients for cosmetic procedures [archive]. February 6, 2007 [updated August 19, 2013]. Available from: https://wayback.archive-it.org/7993/20171105015424/https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm054718.htm. Accessed May 8, 2020.
12. Benowitz NJ, Meister W. Clinical pharmacokinetics of lignocaine. Clin Pharmacokinet. 1978;3:177–201. doi:10.2165/00003088-197803030-00001
13. Guidance for Industry. Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs. U.S. Department of Health and Human Services, Food and Drug Administration, ed. Rockville, MD, USA; 2018. Available from: https://www.fda.gov/media/117569/download. Accessed July 30, 2019.
14. Food and Drug Administration. Assessing Adhesion with Transdermal and Topical Delivery Systems for ANDAs - Guidance for Industry. U.S. Department of Health and Human Services, Food and Drug Administration, ed. Rockville, MD, USA; 2018. Available from: https://www.fda.gov/media/117569/download. Accessed July 30, 2019.

15. Hao J, Ghosh P, Li SK, Newman B, Kasting GB, Raney SG. Heat effects on drug delivery across human skin. Expert Opin Drug Deliv. 2016;13(5):755–768. doi:10.1517/17425247.2016.1136286